Targeted Oncology | NSCLC Case Study
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Advanced Melanoma Responds Well to Pembrolizumab/Ipilimumab Combination
A regimen of pembrolizumab (Keytruda) and low-dose ipilimumab (Yervoy) was effective, and tolerable, for patients with advanced melanoma, according to results from the phase Ib KEYNOTE-029 clinical trial presented by lead investigator Georgina Long, BSc, PhD, MBBS.
Michael Birrer, MD, PhD, on treatments targeting either VEGF or ANG2 in gynecologic cancers.
Therapies in the adjuvant setting like trastuzumab (Herceptin) and neratinib have shown more durable responses in patients with HER2+ breast cancer, as opposed to long-term treatment, said Mohammad Jahanzeb, MD.
Thomas Herzog, MD, on the cautions of interval debulking surgery in ovarian cancer and its difference from neoadjuvant treatment. Herzog said interval debulking surgery entails an initial, maximum surgical effort that is followed up by chemotherapy.
Philip Philip, MD, PhD, professor of oncology at Karmanos Cancer Center, Wayne State University School of Medicine, on treatment options for patients with advanced pancreatic cancer.
Dr. John H. Sampson discusses rindopepimut elimiting brain tumor cells that express the epidermal growth factor receptor mutation variant III (EGFRvIII).
Necitumumab (Portrazza) combined with gemcitabine and cisplatin has been approved by the FDA for the first-line treatment of patients with locally advanced or metastatic squamous NSCLC.
Data showed patients with the HER2-enriched subtype had a high pCR with both single and dual anti-HER2 therapy and a high level of intertumoral heterogeneity.
View More >


HCC Monitor
HCC Monitor
Liver cancer news and updates
Engineered T Cells for Leukemia: A Review of Current Approaches and Applications
This review addresses the basics of CAR T-cell design and reviews data from published clinical studies in leukemia. It also contains commentary on the prospects of this promising new therapeutic strategy.
Hypertension Risk Among Cancer Patients Treated With Sunitinib: A Meta-analysis and Systematic Review
Sunitinib treatment is associated with a significantly increased risk of all-grade and high-grade hypertension.
Evolving Paradigms: Gynecologic Cancer
In the past decade, there has been a rapid increase in the understanding of how various cancers develop and progress, which has led to the advance of novel and more targeted strategies for the prevention, diagnosis, and treatment of many malignancies.
Special Report on Gastrointestinal Cancers
A collection of articles and videos focused on the most recent clinical advances for patients with gastrointestinal cancers.
Updates on New and Emerging Therapies for Neuroendocrine Tumors
This case-based program is designed to educate medical oncologists, surgical oncologists, radiation oncologists, hem-oncs, and other allied health professionals on updates on new and emerging therapies for neuroendocrine tumors.